725 related articles for article (PubMed ID: 8671972)
21. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
Sepandj F; Jindal K; West M; Hirsch D
Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
[TBL] [Abstract][Full Text] [Related]
22. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
[TBL] [Abstract][Full Text] [Related]
23. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
24. Anaemia, iron studies and erythropoietin in patients of chronic renal failure.
Singh NP; Aggarwal L; Singh T; Anuradha S; Kohli R
J Assoc Physicians India; 1999 Mar; 47(3):284-90. PubMed ID: 10999121
[TBL] [Abstract][Full Text] [Related]
25. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
Rao A; Gilg J; Williams A
Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristic of parenteral iron supplementation in hemodialysis patients receiving erythropoietin therapy.
Kao HH; Chen KS; Tsai CJ; Lee CC; Chang HY
Chang Gung Med J; 2000 Oct; 23(10):608-13. PubMed ID: 11126152
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
28. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
29. Administration of the same dose of epoetin-beta intravenously and subcutaneously to patients with renal anaemia.
Steffensen GK; Stergaard O
Scand J Urol Nephrol; 2011 Dec; 45(6):461-9. PubMed ID: 21736448
[TBL] [Abstract][Full Text] [Related]
30. Optimizing erythropoietin therapy in hemodialysis patients.
Richardson D; Bartlett C; Will EJ
Am J Kidney Dis; 2001 Jul; 38(1):109-17. PubMed ID: 11431190
[TBL] [Abstract][Full Text] [Related]
31. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
32. Intravenous ferric saccharate as an iron supplement in dialysis patients.
Silverberg DS; Blum M; Peer G; Kaplan E; Iaina A
Nephron; 1996; 72(3):413-7. PubMed ID: 8852489
[TBL] [Abstract][Full Text] [Related]
33. UK Renal Registry 11th Annual Report (December 2008): Chapter 9 Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analyses.
Richardson D; Ford D; Gilg J; Williams AJ
Nephron Clin Pract; 2009; 111 Suppl 1():c149-83. PubMed ID: 19542697
[TBL] [Abstract][Full Text] [Related]
34. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
35. Intravenous iron treatment in paediatric chronic kidney disease patients not on erythropoietin.
Morgan HE; Holt RC; Jones CA; Judd BA
Pediatr Nephrol; 2007 Nov; 22(11):1963-5. PubMed ID: 17704954
[TBL] [Abstract][Full Text] [Related]
36. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
37. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.
Charytan C; Goldfarb-Rumyantzev A; Wang YF; Schwenk MH; Spinowitz BS
Am J Nephrol; 1998; 18(6):498-503. PubMed ID: 9845824
[TBL] [Abstract][Full Text] [Related]
38. The efficiency of fractionated parenteral iron treatment in CAPD patients.
Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
[TBL] [Abstract][Full Text] [Related]
39. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin.
Stoves J; Inglis H; Newstead CG
Nephrol Dial Transplant; 2001 May; 16(5):967-74. PubMed ID: 11328902
[TBL] [Abstract][Full Text] [Related]
40. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.
Locatelli F; Andrulli S; Memoli B; Maffei C; Del Vecchio L; Aterini S; De Simone W; Mandalari A; Brunori G; Amato M; Cianciaruso B; Zoccali C
Nephrol Dial Transplant; 2006 Apr; 21(4):991-8. PubMed ID: 16384825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]